Navigation Links
Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
Date:9/2/2008

tissue surrounding the tumor. Unrelated clinical studies on radiotherapy correlate the ability to spare more healthy tissue with reduced complications and better outcomes.

Studies Revealed at AAPM

VU Medical Center's studies into the use of Varian RapidArc plans for brain metastases and other key tumor sites were showcased at this year's American Association of Physics in Medicine (AAPM) show in Houston in July. Delivered using a Varian linear accelerator and measured in a solid water phantom, the 25 resulting film measurements showed high agreement with calculations, the VU team concluded. "RapidArc accurately delivers the planned dose distributions," stated Dr. Wilko Verbakel, medical physicist at VU Medical Center.

Dr. Ben Slotman, head of the radiation oncology department of VU University medical center said the hospital, among the first in Europe to introduce Varian's RapidArc, began clinical treatments using this fast and efficient form of volumetric modulated arc therapy in early May and more than 20 patients have so far been treated using the capability. "In the first few months we used RapidArc to replace IMRT treatments for head & neck, brain and prostate tumors but from September onwards RapidArc will replace all conventional IMRT," said Dr. Slotman. "Treatment planning is at least as good, and sometimes even better, than with conventional IMRT and planning and delivery using RapidArc is significantly faster."

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of t
'/>"/>

SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
3. NIH grants $750,000 to develop device to determine temperature of neonates brain
4. InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
5. Scientists create colorful brainbow images of the nervous system
6. Mouse Brain or Impressionist Painting?
7. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
8. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
9. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
10. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
11. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 GOJO, inventors ... its commitment to antibiotic stewardship at the White House ... and animal health organizations and stakeholders at the White ... years to slow the emergence of antibiotic-resistant bacteria, detect ... and prevent the spread of resistant infections. ...
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 German-based ... official United States distributor for the Moenninghoff product ... stated, “I am pleased to announce that the R.M. ... market. For our firm, founded in 1916, this is ... R.M. Hoffman is the kind of professional distributor we ...
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... CHICAGO and RARITAN, N.J. ... & Development, LLC (Janssen) announced data from the ... significant improvement in progression-free survival (PFS) with trabectedin ... with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously ... additional chemotherapy regimen. SAR3007 is the largest randomized ...
Breaking Biology Technology:GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 2GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 4R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... Simple Steps Can Make a Big Difference in Managing ... As this year,s spring nasal allergy season quickly ... to manage their symptoms and ward-off allergens before they ... nasal allergy sufferers prepare for the spring nasal allergy ...
... 2 Epistem Plc,(LSE:EHP) the UK biotechnology and ... a research and development collaboration with Novartis,to identify ... of disease,areas. , The ... programme, with Novartis,s insights into disease pathways &,bioinformatics. ...
... 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... branded generic,pharmaceuticals and innovative anti-cancer pharmaceuticals in the ... to release its 2008,fourth quarter and full year ... opens in the United States. Simcere,s chief executive ...
Cached Biology Technology:Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 2Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 3Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 4Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 5Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 6Epistem Announces Research and Development Collaboration With a Major Pharmaceutical Company 2Simcere Pharmaceutical Group to Announce 2008 Fourth Quarter and Full Year Earnings On Thursday, March 12, 2009 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... University provides molecular-level insights into how cellulose the ... structural component of plant cell walls breaks down ... into any number of useful products, including liquid transportation ... Using a supercomputer that can perform functions thousands of ...
... Ridge, Ill. (December 14, 2012) It is estimated ... prevalent condition known as metabolic syndrome which is a ... factors: large waistline, high triglycerides, low HDL cholesterol, high ... a variety of risk factors that increase the likelihood ...
... 13, 2012 Swift Charities, the charitable arm of ... Fund for Diabetes Research at the Translational Genomics Research ... The Waylon Fund was Swift,s "charity of choice." ... as well as matching contributions from Phoenix-based Swift, were ...
Cached Biology News:Study fuels insight into conversion of wood to bio-oil 2Use 'em, don't lose 'em! Eating egg yolks adds nutritious benefits 2Use 'em, don't lose 'em! Eating egg yolks adds nutritious benefits 3Swift Transportation donates more than $15,000 to the Waylon Fund 2
... Express Cloning Checker Kits provide two highly ... transformation without time-consuming plasmid preparation. By using ... all you need to do is to ... directly from the transformation plates into the ...
Recombinant Equine IL-4, CF...
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
delta-like 1 homolog (Drosophila)...
Biology Products: